Advertisement
Canada markets closed
  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • CAD/USD

    0.7321
    +0.0001 (+0.01%)
     
  • CRUDE OIL

    83.45
    +0.09 (+0.11%)
     
  • Bitcoin CAD

    91,124.53
    -261.38 (-0.29%)
     
  • CMC Crypto 200

    1,430.55
    +15.79 (+1.12%)
     
  • GOLD FUTURES

    2,335.20
    -6.90 (-0.29%)
     
  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     
  • 10-Yr Bond

    4.5980
    -0.0520 (-1.12%)
     
  • NASDAQ futures

    17,711.50
    +104.75 (+0.59%)
     
  • VOLATILITY

    15.69
    -1.25 (-7.38%)
     
  • FTSE

    8,044.81
    +20.94 (+0.26%)
     
  • NIKKEI 225

    38,271.29
    +719.13 (+1.91%)
     
  • CAD/EUR

    0.6834
    -0.0002 (-0.03%)
     

SomaLogic to Announce Second Quarter 2022 Financial Results

SomaLogic, Inc.
SomaLogic, Inc.

BOULDER, Colo. , July 25, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it will report financial results for the second quarter 2022 after market close on Monday, August 15, 2022. Company management will host a corresponding audio webcast beginning at 4:30 p.m. ET.

Those interested in listening to the audio webcast should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at https://investors.somalogic.com/.

About SomaLogic
SomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful, and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s personalized measurement of important changes in an individual’s proteins over time. For more information, visit www.somalogic.com and follow @somalogic on Twitter.

ADVERTISEMENT

SomaSignal™ tests are developed and their performance characteristics determined by SomaLogic, Inc. They have neither been cleared or approved by the US Food and Drug Administration. SomaLogic operates a Clinical Laboratory Improvement Amendments (CLIA) certified, and College of American Pathologists (CAP) accredited laboratory.

Investor Contact
Lauren Glaser
lglaser@somalogic.com

Marissa Bych
Gilmartin Group LLC
marissa@gilmartinir.com

Media Contact
Emilia Costales
720-798-5054
ecostales@somalogic.com